ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 0439

Predictors of Rheumatic Immune-related Adverse Events and de Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor-treatment for Cancer

Amy Cunningham-Bussel1, Jiaqi Wang2, Lauren Prisco3, Lily Martin2, Kathleen Vanni2, Alessandra Zaccardelli2, Mazen Nasrallah4, Lydia Gedmintas2, Lindsey MacFarlane5, Nancy Shadick6, Mark M. Awad7, Osama E. Rahma7, Nicole LeBoeuf8, Ellen Gravallese9 and Jeffrey Sparks2, 1Brigham and Women's, Brookline, MA, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women's Hospital, Pound Ridge, MA, 4MGH, Somerville, MA, 5Brigham and Women's Hospital, Brookline, MA, 6Brigham & Women's Hospital, Boston, MA, 7Dana-Farber Cancer Institute, Boston, 8Brigham and Women's Hospital, Department of Dermatology, Boston, MA, 9Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA

Meeting: ACR Convergence 2021

Keywords: , , ,

Session Information

Date: Saturday, November 6, 2021

Title: Abstracts: Immunological Complications of Therapy (0437–0440)

Session Type: Abstract Session

Session Time: 9:30AM-9:45AM

Background/Purpose: Immune-related adverse events (irAEs) are a frequent and serious complication of immune checkpoint inhibitor (ICI) treatment for cancer, which can resemble primary rheumatic diseases. Predictors associated with development of rheumatic irAEs have not been well characterized in previous studies due to lack of a comparator group and sample size limitations. The aim of this study was to identify predictors at time of ICI initiation associated with rheumatic irAEs as well as de novo inflammatory arthritis, the most common type of rheumatic irAE.

Methods: We performed a case-control study of all cancer patients initiating an ICI at a large tertiary academic health care system and cancer center (2011-2020). We screened for rheumatic irAEs through a comprehensive medical record review of all patients evaluated by a rheumatologist or prescribed an immunomodulator (IM) after initial ICI prescription (baseline), using electronic query. IMs are one of 55 medications used to treat irAEs based on published guidelines. Two board-certified rheumatologists confirmed the presence and type of rheumatic irAE case by independent medical record review. Controls had no pre-existing rheumatic disease, did not receive glucocorticoids, had no IM or rheumatologic evaluation after ICI, and survived at least 6 months after initial ICI (since patients with early demise may not have an opportunity to develop a rheumatic irAE). We found no patients with rheumatic irAEs on medical record review of 100 random controls (negative predictive value 100%). Predictors at the initiation of ICI included: cancer type (the most prevalent cancer, lung cancer was the reference group), ICI regimen, pre-existing autoimmune disease, and glucocorticoid use. Multivariable logistic regression estimated odds ratios (ORs) for rheumatic irAE case status. A similar analysis was performed to find predictors of de novo inflammatory arthritis.

Results: We found 8,028 ICI recipients (mean age 65.5 years, 43.1% female, and 31.8% with lung cancer). We identified 226 (2.8%) confirmed rheumatic irAE cases and 118 (1.5%) with de novo inflammatory arthritis. There were 2,312 controls without rheumatic irAEs included in analyses. Baseline predictors of rheumatic irAE case status were: melanoma (OR 4.01, 2.51-6.40) or genitourinary (GU) cancer (OR 2.19, 1.37-3.48, ref=lung cancer), combination ICI (OR 2.35, 1.48-3.74, ref=PD-1), pre-existing autoimmune disease (OR 2.04, 1.46-2.86), and glucocorticoid use within one year prior to ICI (OR 2.13, 1.51-2.98, ref=non-use) (Figure 1). Baseline predictors of de novo inflammatory arthritis were similar: melanoma (OR 2.95, 1.60-5.43) or GU cancer (OR 2.39, 1.34-4.26, ref=lung cancer), combination ICI (OR 2.31, 1.26-4.26, ref=PD-1), pre-existing autoimmune disease (OR 2.74, 1.79-4.19), and glucocorticoid use one year prior to ICI (OR 1.96, 1.26-3.06, ref=non-use) (Figure 2).

Conclusion: In this large study of patients who received an ICI, we found melanoma, GU cancer, pre-existing autoimmune disease, and glucocorticoid use within 1 year of ICI may be novel predictors of rheumatic irAEs. The possible biologic basis of these associations should be the subject of future research.

Bolded values have p<0.05.
*Controls were patients without rheumatic disease at baseline, used no glucocorticoid or immunomodulator after baseline, and had no rheumatologic evaluation after baseline. Multivariable models were mutually adjusted for all covariates listed in the column.
CCI, Charlson Comorbidity Index; CI, confidence interval; CTLA_4, cytotoxic T-lymphocyte-associated protein 4; ICI, immune checkpoint inhibitors; IM, immunomodulator; irAE, immune-related adverse event; OR, odds ratio; PD_1, programmed cell death protein 1; PD-L1, programmed death ligand 1; REF, Reference.

Bolded values have p<0.05.
*Controls were patients without rheumatic disease at baseline, used no glucocorticoid or immunomodulator after baseline, and had no rheumatologic evaluation after baseline. Multivariable models were mutually adjusted for all covariates listed in the column.
CCI, Charlson Comorbidity Index; CI, confidence interval; CTLA_4, cytotoxic T-lymphocyte-associated protein 4; ICI, immune checkpoint inhibitors; IM, immunomodulator; irAE, immune-related adverse event; OR, odds ratio; PD_1, programmed cell death protein 1; PD-L1, programmed death ligand 1; REF, Reference.

Disclosures: A. Cunningham-Bussel, None; J. Wang, None; L. Prisco, None; L. Martin, None; K. Vanni, None; A. Zaccardelli, None; M. Nasrallah, None; L. Gedmintas, Bristol-Myers Squibb, 5, Amgen, 5, Eli Lilly, 5, Crescendo Biosciences, 5, Sanofi, 5, Mallinckrodt, 5, Bristol-Myers Squibb, 2; L. MacFarlane, None; N. Shadick, Amgen, 5, BMS, 2, 5, Eli Lilly, 5, Sanofi, 5, Mallinckrodt, 5; M. Awad, Genentech, 12, Bristol-Myers Squibb, 12, Merck, 12, AstraZeneca, 5, AstraZeneca, 12, Eli Lilly, 5, Maverick, 12, Blueprint Medicine, 12, Syndax, 12, Ariad, 12, Nektar, 12, Gritstone, 12, ArcherDX, 12, Mirati, 12, NextCure, 12, Novartis, 12, EMD Serono, 12, Panvaxal/NovaRx, 12; O. Rahma, Merck, 5, Merck, 2, BMS, 6, Celgene, 2, Five Prime, 2, GSK, 2, Bayer, 2, Puretech, 12, Roche/Genentech, 2, Puretech, 2, Imvax, 2, Sobi, 2; N. LeBoeuf, Bayer, 2, Seattle Genetics, 2, Sanofi, 2, Silverback, 2, Synox Therapeutics, 2; E. Gravallese, None; J. Sparks, Bristol-Myers Squibb, 2, 5, Amgen, 5, Gilead, 2, Inova, 2, Janssen, 2, Optum, 2, Pfizer, 2.

To cite this abstract in AMA style:

Cunningham-Bussel A, Wang J, Prisco L, Martin L, Vanni K, Zaccardelli A, Nasrallah M, Gedmintas L, MacFarlane L, Shadick N, Awad M, Rahma O, LeBoeuf N, Gravallese E, Sparks J. Predictors of Rheumatic Immune-related Adverse Events and de Novo Inflammatory Arthritis After Immune Checkpoint Inhibitor-treatment for Cancer [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/predictors-of-rheumatic-immune-related-adverse-events-and-de-novo-inflammatory-arthritis-after-immune-checkpoint-inhibitor-treatment-for-cancer/. Accessed .

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictors-of-rheumatic-immune-related-adverse-events-and-de-novo-inflammatory-arthritis-after-immune-checkpoint-inhibitor-treatment-for-cancer/